白细胞介素6在冠心病残余炎症风险中的研究进展
DOI:
作者:
作者单位:

(华中科技大学同济医学院附属协和医院急救中心,湖北省武汉市430023)

作者简介:

张楠,硕士研究生,研究方向为炎症在冠心病中的作用机制,E-mail:zhs20130723@163.com。

通讯作者:

基金项目:

国家自然科学基金面上项目(81570257)


Research progress on the role of interleukin-6 signaling in residual inflammatory risk of coronary heart disease
Author:
Affiliation:

Emergency Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430023, China)

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    冠心病兼具脂质沉积与慢性炎症特征,降脂后仍存在残余心血管风险。白细胞介素6(IL-6)作为上游炎症因子,可通过经典及反式信号激活Janus激酶/信号转导与转录激活因子(JAK/STAT)通路,参与内皮损伤、泡沫细胞形成和斑块不稳定,并诱导C反应蛋白表达。克隆性造血相关的DNA甲基转移酶3A(DNMT3A)、Tet甲基胞嘧啶双加氧酶2(TET2)、额外性梳样蛋白1转录调节因子(ASXL1)及Janus激酶2(JAK2)等基因突变可增强IL-6信号。IL-6单克隆抗体泽韦奇单抗已在Ⅱ期研究中显著降低高敏C反应蛋白、纤维蛋白原等炎症及血栓相关标志物,Ⅲ期心血管结局试验正在进一步验证其对心肌梗死、脑卒中和心血管死亡等硬终点的影响,标志着IL-6靶向治疗已从机制和替代终点研究进入临床结局验证阶段。文章对其机制、遗传驱动及临床意义进行综述,为精准抗炎治疗提供参考。

    Abstract:

    Coronary heart disease is characterized by both lipid deposition and chronic inflammation, and residual cardiovascular risk persists despite lipid-lowering therapy. As an upstream inflammatory cytokine, interleukin-6 (IL-6) activates the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway through classical and trans-signaling, thereby contributing to endothelial injury, foam cell formation, plaque instability, and the induction of C-reactive protein expression. Mutations in clonal hematopoiesis-related genes, including DNA methyltransferase 3 alpha (DNMT3A), Tet methylcytosine dioxygenase 2 (TET2), additional sex combs-like 1 transcriptional regulator (ASXL1), and Janus kinase 2 (JAK2), may further enhance IL-6 signaling. Ziltivekimab, a monoclonal antibody targeting IL-6, has been shown in a phase Ⅱ trial to significantly reduce high-sensitivity C-reactive protein, fibrinogen, and other inflammation- and thrombosis-related biomarkers. A phase Ⅲ cardiovascular outcomes trial is currently evaluating its effects on hard clinical endpoints, including myocardial infarction, stroke, and cardiovascular death, indicating that IL-6-targeted therapy has progressed from mechanistic and surrogate-endpoint studies to clinical outcome validation. This review summarizes the underlying mechanisms, genetic drivers, and clinical significance of IL-6, providing a reference for precision anti-inflammatory therapy in coronary heart disease.

    参考文献
    相似文献
    引证文献
引用本文

张楠,刘本德.白细胞介素6在冠心病残余炎症风险中的研究进展[J].中国动脉硬化杂志,2026,34(10):980~987.

复制
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2026-05-12
  • 最后修改日期:2026-08-10
  • 录用日期:
  • 在线发布日期: 2026-11-19